News & Updates
2026-04
Landmark Paper: Phase II AML clinical trial accepted in Nature Communications
Phase II trial evaluating Quizartinib plus Omacetaxine mepesuccinate in FLT3-ITD AML co-led by Dr. Cheuk-Him Man is published in Nature Communications.
2024-03
Dr. Cheuk-Him Man appointed Associate Professor & Yat-sen Scholar at SYSU
Dr. Cheuk-Him Man joins Sun Yat-sen University School of Medicine as Associate Professor & Ph.D. Supervisor, launching the MCH Laboratory.
2023-12
Major paper in Blood: PLK4 rewires epigenetics to silence cGAS-STING in AML
Revealing that PLK4 inhibition overcomes epigenetic suppression of the cGAS-STING innate immunity pathway in TP53-mutated AML.